Movatterモバイル変換


[0]ホーム

URL:


BRPI0503817A - immunogenic complex formed by nanostructured silica mesoporous encapsulated vaccine antigens - Google Patents

immunogenic complex formed by nanostructured silica mesoporous encapsulated vaccine antigens

Info

Publication number
BRPI0503817A
BRPI0503817ABRPI0503817-0ABRPI0503817ABRPI0503817ABR PI0503817 ABRPI0503817 ABR PI0503817ABR PI0503817 ABRPI0503817 ABR PI0503817ABR PI0503817 ABRPI0503817 ABR PI0503817A
Authority
BR
Brazil
Prior art keywords
immunogenic complex
present
silica
encapsulated
antigen
Prior art date
Application number
BRPI0503817-0A
Other languages
Portuguese (pt)
Inventor
Ogari De Castro Pacheco
Osvaldo Augusto Brazil Es Anna
Lucildes Pita Mercuri
Jivaldo Do Rosario Matos
Marcia Carvalho De Abr Fantini
Original Assignee
Cristalia Prod Quimicos Farm
Fundacao De Amparo A Pesquisa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cristalia Prod Quimicos Farm, Fundacao De Amparo A PesquisafiledCriticalCristalia Prod Quimicos Farm
Priority to BRPI0503817-0ApriorityCriticalpatent/BRPI0503817A/en
Priority to PCT/BR2006/000182prioritypatent/WO2007030901A1/en
Priority to US12/066,489prioritypatent/US8642258B2/en
Priority to KR1020087007043Aprioritypatent/KR101089400B1/en
Priority to CN2006800383996Aprioritypatent/CN101287491B/en
Priority to ES06775036Tprioritypatent/ES2423892T3/en
Priority to EP06775036.4Aprioritypatent/EP1942934B1/en
Priority to HK09102975.6Aprioritypatent/HK1124791B/en
Priority to CA2621373Aprioritypatent/CA2621373C/en
Priority to JP2008530281Aprioritypatent/JP5091863B2/en
Publication of BRPI0503817ApublicationCriticalpatent/BRPI0503817A/en
Priority to ZA200802277Aprioritypatent/ZA200802277B/en

Links

Classifications

Landscapes

Abstract

Translated fromPortuguese

COMPLEXO IMUNOGêNICO FORMADO POR ANTìGENOS VACINAIS ENCAPSULADOS POR SìLICA MESOPOROSA NANOESTRUTURA A presente invenção refere-se a um produto dito "complexo imunogênico" que compreende um adjuvante caracterizado por partículas sólidas de sílica mesoporosa nanoestruturada altamente ordenada, preferentemente a sílica SBA-15, e antígenos vacinais de naturezas diversas encapsulados nos ditos adjuvantes. O complexo imunogênico da presente invenção permite a apresentação dos antígenos que o compõe aos linfócitos de maneira segura, gradual e prolongada que leva a uma memória imunológica mais eficiente, aumenta a imunogenicidade do antígeno e melhora a produção de anticorpos. Isto garante uma proteção imunológica eficiente com menores quantidades de antígenos e/ou menos repetições de doses vacinais. Alem disso as características do complexo imunogênico da presente invenção promovem efetiva indução de imunidade de maneira homogênea em indivíduos "bons e maus respondedores".IMMUNOGENIC COMPLEX FORMED BY VACCIN ANTIGENS ENCAPSULATED BY NANOSTRUCTURE SILICA MESOPOROSA The present invention relates to an "immunogenic complex" product comprising an adjuvant characterized by solid particles of highly ordered nanostructured mesoporous silica, preferably SBA-15 antigenic silica of various natures encapsulated in said adjuvants. The immunogenic complex of the present invention allows the presentation of the antigen that composes it to lymphocytes in a safe, gradual and prolonged way that leads to a more efficient immunological memory, increases antigen immunogenicity and improves antibody production. This ensures efficient immunological protection with lower antigen amounts and / or fewer repeat vaccine doses. Furthermore, the characteristics of the immunogenic complex of the present invention promote effective homogeneous induction of immunity in "good and bad responders" individuals.

BRPI0503817-0A2005-09-122005-09-12 immunogenic complex formed by nanostructured silica mesoporous encapsulated vaccine antigensBRPI0503817A (en)

Priority Applications (11)

Application NumberPriority DateFiling DateTitle
BRPI0503817-0ABRPI0503817A (en)2005-09-122005-09-12 immunogenic complex formed by nanostructured silica mesoporous encapsulated vaccine antigens
ES06775036TES2423892T3 (en)2005-09-122006-09-12 Immune complex formed by vaccine antigens encapsulated with nanostructured mesoporous silica
US12/066,489US8642258B2 (en)2005-09-122006-09-12Immunogenical complex formed by vaccinal antigens encapsulated by nanostructured mesoporous silica
KR1020087007043AKR101089400B1 (en)2005-09-122006-09-12Immunogenic complex formed by vaccinal antigens encapsulated by nanostructured mesoporous silica
CN2006800383996ACN101287491B (en)2005-09-122006-09-12 Immunogenic complexes formed from vaccine antigens encapsulated using nanostructured mesoporous silica
PCT/BR2006/000182WO2007030901A1 (en)2005-09-122006-09-12Immunogenic complex formed by vaccinal antigens encapsulated by nanostructured mesoporous silica
EP06775036.4AEP1942934B1 (en)2005-09-122006-09-12Immunogenic complex formed by vaccinal antigens encapsulated by nanostructured mesoporous silica
HK09102975.6AHK1124791B (en)2005-09-122006-09-12Immunogenic complex formed by vaccinal antigens encapsulated by nanostructured mesoporous silica
CA2621373ACA2621373C (en)2005-09-122006-09-12Immunogenic complex formed by vaccinal antigens encapsulated by nanostructured mesoporous silica
JP2008530281AJP5091863B2 (en)2005-09-122006-09-12 Immunogenic complexes consisting of vaccine antigens incorporated into nanostructured mesoporous silica
ZA200802277AZA200802277B (en)2005-09-122008-03-10Immunogenic complex formed by vaccinal antigens encapsulated by nanostructured mesoporous silica

Applications Claiming Priority (1)

Application NumberPriority DateFiling DateTitle
BRPI0503817-0ABRPI0503817A (en)2005-09-122005-09-12 immunogenic complex formed by nanostructured silica mesoporous encapsulated vaccine antigens

Publications (1)

Publication NumberPublication Date
BRPI0503817Atrue BRPI0503817A (en)2007-05-15

Family

ID=37864579

Family Applications (1)

Application NumberTitlePriority DateFiling Date
BRPI0503817-0ABRPI0503817A (en)2005-09-122005-09-12 immunogenic complex formed by nanostructured silica mesoporous encapsulated vaccine antigens

Country Status (10)

CountryLink
US (1)US8642258B2 (en)
EP (1)EP1942934B1 (en)
JP (1)JP5091863B2 (en)
KR (1)KR101089400B1 (en)
CN (1)CN101287491B (en)
BR (1)BRPI0503817A (en)
CA (1)CA2621373C (en)
ES (1)ES2423892T3 (en)
WO (1)WO2007030901A1 (en)
ZA (1)ZA200802277B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
WO2018102896A1 (en)*2016-12-052018-06-14Universidade Estadual De Campinas - UnicampVaccine forhaemophilus aegypus and use

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
BRPI0503817A (en)2005-09-122007-05-15Cristalia Prod Quimicos Farm immunogenic complex formed by nanostructured silica mesoporous encapsulated vaccine antigens
AU2006326405B2 (en)2005-12-132013-10-31President And Fellows Of Harvard CollegeScaffolds for cell transplantation
US9770535B2 (en)2007-06-212017-09-26President And Fellows Of Harvard CollegeScaffolds for cell collection or elimination
CN102006891B (en)2008-02-132017-04-26哈佛学院董事会Continuous cell programming device
US9370558B2 (en)2008-02-132016-06-21President And Fellows Of Harvard CollegeControlled delivery of TLR agonists in structural polymeric devices
US9012399B2 (en)2008-05-302015-04-21President And Fellows Of Harvard CollegeControlled release of growth factors and signaling molecules for promoting angiogenesis
DE102008033175A1 (en)*2008-07-152010-01-21Merck Patent Gmbh Silica nanoparticles and their use for vaccination
JP2010083834A (en)*2008-10-012010-04-15Naris Cosmetics Co LtdAllergen inactivator and cosmetic product containing the same
US9297005B2 (en)2009-04-132016-03-29President And Fellows Of Harvard CollegeHarnessing cell dynamics to engineer materials
EP2461828B1 (en)2009-07-312017-06-21President and Fellows of Harvard CollegeProgramming of cells for tolerogenic therapies
WO2011109834A2 (en)2010-03-052011-09-09President And Fellows Of Harvard CollegeEnhancement of skeletal muscle stem cell engrafment by dual delivery of vegf and igf-1
US9693954B2 (en)2010-06-252017-07-04President And Fellows Of Harvard CollegeCo-delivery of stimulatory and inhibitory factors to create temporally stable and spatially restricted zones
PL2624873T3 (en)2010-10-062020-12-14President And Fellows Of Harvard CollegeInjectable, pore-forming hydrogels for materials-based cell therapies
WO2012064697A2 (en)2010-11-082012-05-18President And Fellows Of Harvard CollegeMaterials presenting notch signaling molecules to control cell behavior
WO2012148684A1 (en)2011-04-272012-11-01President And Fellows Of Harvard CollegeCell-friendly inverse opal hydrogels for cell encapsulation, drug and protein delivery, and functional nanoparticle encapsulation
US9675561B2 (en)2011-04-282017-06-13President And Fellows Of Harvard CollegeInjectable cryogel vaccine devices and methods of use thereof
EP3417876B1 (en)2011-04-282021-03-31President and Fellows of Harvard CollegeInjectable preformed macroscopic 3-dimensional scaffolds for minimally invasive administration
US9486512B2 (en)2011-06-032016-11-08President And Fellows Of Harvard CollegeIn situ antigen-generating cancer vaccine
CN103012594B (en)*2011-09-222015-09-02中国农业科学院兰州兽医研究所A kind of nano-carrier and application delivering pig circular ring virus epitope protein
JP5999639B2 (en)*2011-11-252016-09-28国立研究開発法人産業技術総合研究所 Immunostimulating factor-bearing microparticle
EP2838515B1 (en)*2012-04-162019-11-20President and Fellows of Harvard CollegeMesoporous silica compositions for modulating immune responses
ES2821528T3 (en)2012-11-142021-04-26Grace W R & Co Compositions containing a biologically active material and an unordered inorganic oxide
EP2981249A4 (en)*2013-04-022016-11-23Stc UnmMesoporous alum nanoparticles as universal platform for antigen adsorption, presentation, and delivery
AU2014366842B2 (en)*2013-12-192018-10-04The University Of QueenslandMethod of synthesis of silica vesicles and use thereof
WO2015168379A2 (en)2014-04-302015-11-05President And Fellows Of Harvard CollegeCombination vaccine devices and methods of killing cancer cells
CN105267970A (en)*2015-01-082016-01-27浙江大学Thermostable vaccine with silica on surface and preparation method therefor
CA3012602A1 (en)2015-01-302016-08-04President And Fellows Of Harvard CollegePeritumoral and intratumoral materials for cancer therapy
WO2016164705A1 (en)2015-04-102016-10-13Omar Abdel-Rahman AliImmune cell trapping devices and methods for making and using the same
JP6868862B2 (en)*2015-08-312021-05-12国立研究開発法人産業技術総合研究所 Mesoporous silica particles
CN105597094A (en)*2015-12-312016-05-25河南农业大学Pig transmissible gastroenteritis virus nanometer silicon adjuvant inactivated vaccine and preparation method thereof
WO2017120504A1 (en)2016-01-082017-07-13Durfee Paul NOsteotropic nanoparticles for prevention or treatment of bone metastases
CN115531609A (en)2016-02-062022-12-30哈佛学院校长同事会Remodeling hematopoietic niches to reconstitute immunity
CN115404196A (en)2016-07-132022-11-29哈佛学院院长等 Antigen-presenting cell mimic scaffold and methods for its preparation and use
JP7274214B2 (en)2016-08-022023-05-16プレジデント アンド フェローズ オブ ハーバード カレッジ Biomaterials for modulating immune responses
GB2552704A (en)*2016-08-042018-02-07Univ BathBiomolecule preservation
CN106727426A (en)*2016-12-082017-05-31中国药科大学A kind of preparation method for oral protein immune carrier
US11344629B2 (en)2017-03-012022-05-31Charles Jeffrey BrinkerActive targeting of cells by monosized protocells
WO2020061129A1 (en)2018-09-192020-03-26President And Fellows Of Harvard CollegeCompositions and methods for labeling and modulation of cells in vitro and in vivo
US12252708B2 (en)2018-09-242025-03-18Unm Rainforest InnovationsLiving mammalian cells modified with functional modular nanoparticles
US12208164B2 (en)2019-02-282025-01-28Unm Rainforest InnovationsModular metal-organic polyhedra superassembly compositions
CN114377120B (en)*2022-01-102023-09-22大连理工大学Construction and application of silica vaccine delivery system with virus-like particles as templates

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US5102643A (en)1990-01-251992-04-07Mobil Oil Corp.Composition of synthetic porous crystalline material, its synthesis
US5057296A (en)1990-12-101991-10-15Mobil Oil Corp.Method for synthesizing mesoporous crystalline material
AU7881000A (en)1999-08-162001-03-13Henceforth Hibernia, Inc.Therapeutic and prophylactic compositions including catalytic biomimetic solids and methods to prepare and use them
US20020051794A1 (en)2000-08-092002-05-02Alk-Abello A/SNovel parenteral vaccine formulations and uses thereof
GB0118689D0 (en)*2001-08-012001-09-19Psimedica LtdPharmaceutical formulation
CN1193818C (en)*2002-03-132005-03-23华东理工大学Silicone dioxide magnetic microsphere and its preparation method
US20040005352A1 (en)*2002-04-162004-01-08Lopez Gabriel P.Biologically functionalized porous microspheres
JP2004083501A (en)*2002-08-282004-03-18Toyota Central Res & Dev Lab Inc Stabilized antibody, immunoreaction method and immunoreaction device using the same
JP2004155745A (en)*2002-11-082004-06-03Kumamoto Technology & Industry FoundationPeptide and its use
US20040101822A1 (en)*2002-11-262004-05-27Ulrich WiesnerFluorescent silica-based nanoparticles
JP2004321010A (en)*2003-04-212004-11-18Japan Science & Technology Agency Novel streptococcal protein antigen
US20060018966A1 (en)*2003-07-222006-01-26Lin Victor SAntimicrobial mesoporous silica nanoparticles
US7563451B2 (en)*2003-07-222009-07-21Iowa State University Research Foundation, Inc.Capped mesoporous silicates
JP4429105B2 (en)*2003-08-192010-03-10キヤノン株式会社 Organic substance-immobilized structure and production method thereof, peptide and DNA
BRPI0503817A (en)2005-09-122007-05-15Cristalia Prod Quimicos Farm immunogenic complex formed by nanostructured silica mesoporous encapsulated vaccine antigens

Cited By (1)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
WO2018102896A1 (en)*2016-12-052018-06-14Universidade Estadual De Campinas - UnicampVaccine forhaemophilus aegypus and use

Also Published As

Publication numberPublication date
KR101089400B1 (en)2011-12-07
EP1942934B1 (en)2013-05-01
JP5091863B2 (en)2012-12-05
ZA200802277B (en)2009-01-28
HK1124791A1 (en)2009-07-24
CN101287491A (en)2008-10-15
CA2621373C (en)2014-05-27
JP2009507859A (en)2009-02-26
CN101287491B (en)2013-01-30
ES2423892T3 (en)2013-09-25
WO2007030901A1 (en)2007-03-22
US20080286371A1 (en)2008-11-20
US8642258B2 (en)2014-02-04
CA2621373A1 (en)2007-03-22
EP1942934A1 (en)2008-07-16
KR20080047569A (en)2008-05-29

Similar Documents

PublicationPublication DateTitle
BRPI0503817A (en) immunogenic complex formed by nanostructured silica mesoporous encapsulated vaccine antigens
Shah et al.Overview of vaccine adjuvants: introduction, history, and current status
Azmi et al.Recent progress in adjuvant discovery for peptide-based subunit vaccines
Puggioni et al.Monophosphoryl lipid A (MPL®)* promotes allergen‐induced immune deviation in favour of Th1 responses
TW200722101A (en)Novel composition
EA200900024A1 (en) Anti-throat vaccine
Pfaar et al.Adjuvants for immunotherapy
Klimek et al.Clinical use of adjuvants in allergen-immunotherapy
Martiñón et al.Chemical and immunological characteristics of aluminum‐based, oil‐water emulsion, and bacterial‐origin adjuvants
CY1113546T1 (en) WATER OIL MILK EMULSIONS AND VACCINATION COMPOSITIONS
BRPI0206672B8 (en) immunological composition, tetravalent conjugate vaccine and multivalent meningococcal vaccine
DK2468300T3 (en) Vaccine composition containing synthetic adjuvant
KR20130112790A (en)Vaccine composition
Pérez et al.New vaccines require potent adjuvants like AFPL1 and AFCo1
EP2455101A3 (en)Influenza vaccine with oil-in-water emulsion adjuvant
EP2481422A3 (en)Multiplex vaccines
WO2007068907A3 (en)Vaccine compositions comprising a saponin adjuvant
JP2014531396A (en) Pharmaceutical composition containing a combination of a selective carrier, vitamin, tannin and flavonoid as an antigen-specific immune modulator
BR0314373A (en) Stable immunogenic product for the induction of antibodies to one or more antigenic proteins in a subject, pharmaceutical, immunogenic and vaccine compositions and process of preparation of an immunogenic product
Burakova et al.Food‐Grade Saponin Extract as an Emulsifier and Immunostimulant in Emulsion‐Based Subunit Vaccine for Pigs
BRPI0515334A (en) use of a plasmodium antigen
GB2442408A (en)Vaccine adjuvants
Pérez et al.Natural Neisseria derive proteoliposome and cochleate as potent vaccine adjuvants
BR112014012184A2 (en) malaria vaccine
Sohrabi et al.Evaluation of immune response against leishmaniasis in resistance C57 BL/6 mice immunized with liposomes containing autoclaved Leishmania major with BCG

Legal Events

DateCodeTitleDescription
B06FObjections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07DTechnical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07ENotification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B09ADecision: intention to grant [chapter 9.1 patent gazette]
B16APatent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text:PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 11/07/2017, OBSERVADAS AS CONDICOES LEGAIS.

B21FLapse acc. art. 78, item iv - on non-payment of the annual fees in time
B24JLapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text:EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2479 DE 10-07-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.


[8]ページ先頭

©2009-2025 Movatter.jp